Cargando…

Comorbidities, sequelae, blood biomarkers and their associated clinical outcomes in the Mount Sinai Health System COVID-19 patients

With the continuing rise of SARS-CoV2 infection globally and the emergence of various waves in different countries, understanding characteristics of susceptibility to infection, clinical severity, and outcomes remain vital. In this retrospective study, data was extracted for 39,539 patients from the...

Descripción completa

Detalles Bibliográficos
Autores principales: Brojakowska, Agnieszka, Eskandari, Abrisham, Bisserier, Malik, Bander, Jeffrey, Garikipati, Venkata Naga Srikanth, Hadri, Lahouaria, Goukassian, David A., Fish, Kenneth M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260001/
https://www.ncbi.nlm.nih.gov/pubmed/34228746
http://dx.doi.org/10.1371/journal.pone.0253660
_version_ 1783718752535183360
author Brojakowska, Agnieszka
Eskandari, Abrisham
Bisserier, Malik
Bander, Jeffrey
Garikipati, Venkata Naga Srikanth
Hadri, Lahouaria
Goukassian, David A.
Fish, Kenneth M.
author_facet Brojakowska, Agnieszka
Eskandari, Abrisham
Bisserier, Malik
Bander, Jeffrey
Garikipati, Venkata Naga Srikanth
Hadri, Lahouaria
Goukassian, David A.
Fish, Kenneth M.
author_sort Brojakowska, Agnieszka
collection PubMed
description With the continuing rise of SARS-CoV2 infection globally and the emergence of various waves in different countries, understanding characteristics of susceptibility to infection, clinical severity, and outcomes remain vital. In this retrospective study, data was extracted for 39,539 patients from the de-identified Mount Sinai Health System COVID-19 database. We assessed the risk of mortality based on the presence of comorbidities and organ-specific sequelae in 7,032 CoV2 positive (+) patients. Prevalence of cardiovascular and metabolic comorbidities was high among SARS-CoV2+ individuals. Diabetes, obesity, coronary artery disease, hypertension, atrial fibrillation, and heart failure all increased overall mortality risk, while asthma did not. Ethnicity modified the risk of mortality associated with these comorbidities. With regards to secondary complications in the setting of infection, individuals with acute kidney injury and acute myocardial injury showed an increase in mortality risk. Cerebral infarcts and acute venous thromboembolic events were not associated with increased risk of mortality. Biomarkers for cardiovascular injury, coagulation, and inflammation were compared between deceased and survived individuals. We found that cardiac and coagulation biomarkers were elevated and fell beyond normal range more often in deceased patients. Several, but not all, inflammatory markers evaluated were increased in deceased patients. In summary, we identified comorbidities and sequelae along with peripheral blood biomarkers that were associated with elevated clinical severity and poor outcomes in COVID-19 patients. Overall, these findings detail the granularity of previously reported factors which may impact susceptibility, clinical severity, and mortality during the course of COVID-19 disease.
format Online
Article
Text
id pubmed-8260001
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-82600012021-07-19 Comorbidities, sequelae, blood biomarkers and their associated clinical outcomes in the Mount Sinai Health System COVID-19 patients Brojakowska, Agnieszka Eskandari, Abrisham Bisserier, Malik Bander, Jeffrey Garikipati, Venkata Naga Srikanth Hadri, Lahouaria Goukassian, David A. Fish, Kenneth M. PLoS One Research Article With the continuing rise of SARS-CoV2 infection globally and the emergence of various waves in different countries, understanding characteristics of susceptibility to infection, clinical severity, and outcomes remain vital. In this retrospective study, data was extracted for 39,539 patients from the de-identified Mount Sinai Health System COVID-19 database. We assessed the risk of mortality based on the presence of comorbidities and organ-specific sequelae in 7,032 CoV2 positive (+) patients. Prevalence of cardiovascular and metabolic comorbidities was high among SARS-CoV2+ individuals. Diabetes, obesity, coronary artery disease, hypertension, atrial fibrillation, and heart failure all increased overall mortality risk, while asthma did not. Ethnicity modified the risk of mortality associated with these comorbidities. With regards to secondary complications in the setting of infection, individuals with acute kidney injury and acute myocardial injury showed an increase in mortality risk. Cerebral infarcts and acute venous thromboembolic events were not associated with increased risk of mortality. Biomarkers for cardiovascular injury, coagulation, and inflammation were compared between deceased and survived individuals. We found that cardiac and coagulation biomarkers were elevated and fell beyond normal range more often in deceased patients. Several, but not all, inflammatory markers evaluated were increased in deceased patients. In summary, we identified comorbidities and sequelae along with peripheral blood biomarkers that were associated with elevated clinical severity and poor outcomes in COVID-19 patients. Overall, these findings detail the granularity of previously reported factors which may impact susceptibility, clinical severity, and mortality during the course of COVID-19 disease. Public Library of Science 2021-07-06 /pmc/articles/PMC8260001/ /pubmed/34228746 http://dx.doi.org/10.1371/journal.pone.0253660 Text en © 2021 Brojakowska et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Brojakowska, Agnieszka
Eskandari, Abrisham
Bisserier, Malik
Bander, Jeffrey
Garikipati, Venkata Naga Srikanth
Hadri, Lahouaria
Goukassian, David A.
Fish, Kenneth M.
Comorbidities, sequelae, blood biomarkers and their associated clinical outcomes in the Mount Sinai Health System COVID-19 patients
title Comorbidities, sequelae, blood biomarkers and their associated clinical outcomes in the Mount Sinai Health System COVID-19 patients
title_full Comorbidities, sequelae, blood biomarkers and their associated clinical outcomes in the Mount Sinai Health System COVID-19 patients
title_fullStr Comorbidities, sequelae, blood biomarkers and their associated clinical outcomes in the Mount Sinai Health System COVID-19 patients
title_full_unstemmed Comorbidities, sequelae, blood biomarkers and their associated clinical outcomes in the Mount Sinai Health System COVID-19 patients
title_short Comorbidities, sequelae, blood biomarkers and their associated clinical outcomes in the Mount Sinai Health System COVID-19 patients
title_sort comorbidities, sequelae, blood biomarkers and their associated clinical outcomes in the mount sinai health system covid-19 patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260001/
https://www.ncbi.nlm.nih.gov/pubmed/34228746
http://dx.doi.org/10.1371/journal.pone.0253660
work_keys_str_mv AT brojakowskaagnieszka comorbiditiessequelaebloodbiomarkersandtheirassociatedclinicaloutcomesinthemountsinaihealthsystemcovid19patients
AT eskandariabrisham comorbiditiessequelaebloodbiomarkersandtheirassociatedclinicaloutcomesinthemountsinaihealthsystemcovid19patients
AT bisseriermalik comorbiditiessequelaebloodbiomarkersandtheirassociatedclinicaloutcomesinthemountsinaihealthsystemcovid19patients
AT banderjeffrey comorbiditiessequelaebloodbiomarkersandtheirassociatedclinicaloutcomesinthemountsinaihealthsystemcovid19patients
AT garikipativenkatanagasrikanth comorbiditiessequelaebloodbiomarkersandtheirassociatedclinicaloutcomesinthemountsinaihealthsystemcovid19patients
AT hadrilahouaria comorbiditiessequelaebloodbiomarkersandtheirassociatedclinicaloutcomesinthemountsinaihealthsystemcovid19patients
AT goukassiandavida comorbiditiessequelaebloodbiomarkersandtheirassociatedclinicaloutcomesinthemountsinaihealthsystemcovid19patients
AT fishkennethm comorbiditiessequelaebloodbiomarkersandtheirassociatedclinicaloutcomesinthemountsinaihealthsystemcovid19patients